Clicky

Mesoblast limited  (MSB)

Description: Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.


Keywords: Medicine Biotechnology Life Sciences Biology Disease Stem Cell Disorders Cell Biology Induced Stem Cells Adult Stem Cell Regenerative Biomedicine Mesoblast Orthopedic Disorders

Home Page: www.mesoblast.com

MSB Technical Analysis

Massmutual Select Funds
,

Phone: 61 3 9639 6036


Officers

Name Title
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director
Dr. Eric A. Rose M.D. Chief Medical Officer & Exec. Director
Mr. Andrew Chaponnel B.Com. Interim Chief Fin. Officer
Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. Chief Operating Officer
Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) Gen. Counsel & Corp. Exec.
Mr. Roger D. Brown BA Head of Spinal Orthopedic Disorders
Mr. Michael Schuster M.B.A., MS, BSc, MBA Head of Pharma Partnering
Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA Head of Regulatory Affairs & Quality Management
Mr. Justin Horst B.S. Head of Manufacturing
Ms. Niva Sivakumar B.Com., L.L.B. Joint Company Sec.

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 769.2308
Trailing PE: 0
Price-to-Book MRQ: 0.8277
Price-to-Sales TTM: 86.176
IPO Date:
Fiscal Year End: June
Full Time Employees: 77
Back to stocks